1. Prevalence and dynamics of antimalarial drug resistance mutations among the Plasmodium falciparum isolates in TAK Province, Thailand, during the period of 1998-2001.
- Author
-
Thaloengsok S, Chaisatit C, Saingam P, Lertsethtakarn P, Spring M, Sriwichai S, Pholwat S, Guler JL, Houpt ER, and Vesely BA
- Subjects
- Thailand epidemiology, Humans, Retrospective Studies, Prevalence, Mefloquine pharmacology, Mefloquine therapeutic use, Animals, Artemisinins pharmacology, Artemisinins therapeutic use, Pyrimethamine pharmacology, Pyrimethamine therapeutic use, Sulfadoxine pharmacology, Sulfadoxine therapeutic use, Drug Combinations, Plasmodium falciparum drug effects, Plasmodium falciparum genetics, Antimalarials pharmacology, Antimalarials therapeutic use, Drug Resistance genetics, Mutation, Malaria, Falciparum parasitology, Malaria, Falciparum epidemiology, Malaria, Falciparum drug therapy
- Abstract
Despite the overall decline in malaria cases in Thailand, continuous surveillance in endemic areas remains crucial. This retrospective analysis examined Plasmodium falciparum samples from Tak province, Thailand, collected in 1998, 1999, and 2001, to investigate the prevalence and evolution of antimalarial genotypic drug resistance. The study revealed a high prevalence of drug-resistant P. falciparum , particularly to mefloquine and sulfadoxine/pyrimethamine, with significant mutations in genes associated with resistance. Notably, mutations indicative of artemisinin resistance, such as those in the kelch13 gene, were detected at low frequencies, suggesting an evolving resistance pattern. The underlying cause of these resistance mutations appears to be the historical and widespread use of these antimalarial drugs, which exerted selective pressure on the parasite population. These findings underscore the necessity of ongoing surveillance and adaptive control strategies to manage drug resistance, guide treatment policies, and prevent potential outbreaks, even as malaria cases decrease. Continuous monitoring and research are imperative to sustain malaria elimination efforts and address the dynamic challenges posed by evolving drug-resistant strains., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF